张晓辉, 徐雅莉, 孙强, 潘博, 周易冬, 茅枫, 关竞红, 林燕. 腋窝淋巴结阴性浸润性乳腺癌分子分型的表达及预后分析[J]. 中国肿瘤临床, 2014, 41(12): 793-796. DOI: 10.3969/j.issn.1000-8179.20140283
引用本文: 张晓辉, 徐雅莉, 孙强, 潘博, 周易冬, 茅枫, 关竞红, 林燕. 腋窝淋巴结阴性浸润性乳腺癌分子分型的表达及预后分析[J]. 中国肿瘤临床, 2014, 41(12): 793-796. DOI: 10.3969/j.issn.1000-8179.20140283
shu
ZHANG Xiaohui, XU Yahli, SUN Qiang, PAN Bo, ZHOU Yidong, MAO Feng, GUAN Jinghong, LIN Yan. Molecular subtype and its association with prognosis in axillary lymph node-negative invasive breast cancer patients[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2014, 41(12): 793-796. DOI: 10.3969/j.issn.1000-8179.20140283
Citation: ZHANG Xiaohui, XU Yahli, SUN Qiang, PAN Bo, ZHOU Yidong, MAO Feng, GUAN Jinghong, LIN Yan. Molecular subtype and its association with prognosis in axillary lymph node-negative invasive breast cancer patients[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2014, 41(12): 793-796. DOI: 10.3969/j.issn.1000-8179.20140283
shu

腋窝淋巴结阴性浸润性乳腺癌分子分型的表达及预后分析

Molecular subtype and its association with prognosis in axillary lymph node-negative invasive breast cancer patients

    摘要
  • 摘要:
      目的   探讨腋窝淋巴结阴性浸润性乳腺癌不同分子分型的分布，临床病理特征以及和预后的关系。
      方法   回顾性分析183例该类乳腺癌患者的临床病理资料，对管腔上皮（Luminal）型、基底样（Basal-1ike）型和HER-2过表达（over-expression）型乳腺癌患者在年龄、肿瘤大小、临床分期和无瘤生存率（disease-free survival，DFS）、总生存率（overall survival，OS）方面进行统计分析。
      结果   不同分子亚型乳腺癌在年龄、肿瘤大小、临床分期方面无显著性差异。Luminal、Basal-like、HER-2过表达型的复发率分别为3.9%（4/102）、20.4%（10/49）、6.3%（2/32）（P=0.002）；死亡率分别为2.0%（2/102）、6.1%（3/49）、3.1%（1/32）（P>0.05）。Ka-plan-Meier分析显示Basal-like型的DFS最低（P=0.002），Basal-like型的OS较低（P=0.39）。Cox多因素比例风险模型分析显示分子亚型对DFS存在显著影响（P=0.001）。
      结论   在腋窝淋巴结阴性浸润性乳腺癌患者中，不同分子亚型在年龄、肿瘤大小及临床分期方面无显著性差异，Basal-like型预后最差，分子分型是其独立预后指标。

     

    Abstract:
      Objective   To analyze the distribution, clinico-pathologic features, and survival status of different subtypes in axillary lymph node-negative invasive breast cancer patients.
      Methods   In this study, data of 183 patients were included and retrospectively analyzed in terms of age distribution, clinico-pathologic features, disease-free survival (DFS), and overall survival based on different subtypes (luminal, basal-like, and HER-2 over-expression).
      Results   No significant differences in age, tumor size, and TNM stage was observed among different subtypes. The relapse rates of luminal, basal-like, and HER-2 over-expression subtypes were 3.9% (4/102), 20.4% (10/49), and 6.3% (2/32), respectively (P=0.002). The death rates of luminal, basal-like, and HER-2 over-expression subtypes were 2.0% (2/102), 6.1% (3/49), and 3.1% (1/32), respectively (P>0.05). Kaplan-Meier analysis showed that the DFS of basal-like subtype was much lower compared with that of the luminal and HER-2 over-expression subtypes (P=0.002). Cox analysis showed that the subtype was an independent prognostic indicator (P=0.001).
      Conclusion   In node-negative invasive breast cancer, no significant differences in age distribution, tumor size, and TNM stage was observed among different subtypes. The basal-like subtype has the worst prognosis. Therefore, subtype is an important independent prognostic indicator.

     

    • HTML全文
    • 参考文献(15)
    • 相关文章
    • 施引文献
  • 资源附件(0)

/

返回文章
返回